ArticleAnnals of medicine2023
Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019.
Article in Annals of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2026Article
- Association Between Cirrhosis and Acute or Severe Limb Ischemic Events Among Hospitalizations with Peripheral Artery Disease: A National Inpatient Sample Analysis.Medicina (Kaunas, Lithuania) · 2026Article
- Single-cell atlas of hepatic cellular plasticity and immune niche reprogramming in liver cirrhosis.Journal of translational medicine · 2026Article
- Association of NT-proBNP and sST2 with Diastolic Dysfunction in Cirrhotic Patients and Its Therapeutic Implications.International journal of molecular sciences · 2025Article
- Etiology of cirrhosis is associated with risk of hepatic decompensation and hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Prevalence of occult hepatitis B infection and hepatitis B genotype characterization among blood donors in Jember Regency, East Java, Indonesia.BMC infectious diseases · 2025Article
- Regional Mortality From Chronic Liver Diseases in African Countries Attributable to Hepatitis B Virus and Hepatitis C Virus Infections From 1990 to 2021 and Projections to 2030.Open forum infectious diseases · 2025Article
- Shared and Context-Specific Mechanisms of EMT and Cellular Plasticity in Cancer and Fibrotic Diseases.International journal of molecular sciences · 2025Review
- Global burden of mental disorders in 204 countries and territories results from the Global Burden of Disease Study 2021.World journal of psychiatry · 2025Article
- Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.Life (Basel, Switzerland) · 2025Review
- An Update on the Role of Alanine Aminotransferase in the Detection of Chronic Liver Diseases Relevant to Primary Care.Oman medical journal · 2025Review
- Circular RNAs in Liver Diseases.Advances in experimental medicine and biology · 2025Review
- Global burden of liver cirrhosis 1990-2019 and 20 years forecast: results from the global burden of disease study 2019.Annals of medicine · 2024Article
- The burden of cirrhosis and other chronic liver disease in the middle east and North Africa (MENA) region over three decades.BMC public health · 2024Article
- Expression and predictive value of serum core fucosylated low molecular weight kininogen and alpha-galactosylated antibodies in patients with hepatic fibrosis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- The role of anoctamin 1 in liver disease.Journal of cellular and molecular medicine · 2024Review
- Cutaneous Mucormycosis in a Patient With Cirrhosis: A Case Report.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver cirrhosis is a significant yet largely preventable and underappreciated cause of global health loss. This study aimed to profile the global and regional burdens of liver cirrhosis between 2010 and 2019 and the contributions of various aetiologies.
methodData on the incidence, mortality, and disability-adjusted life years (DALYs) of cirrhosis were obtained from the Global Burden of Disease 2019 study. The burden of cirrhosis was estimated by age, sex, region, aetiology, and socio-demographic index (SDI). The temporal trend was quantified using the annual percentage changes (APC.).
resultsGlobally, there were 2.05 million new cases and 1.47 million deaths due to cirrhosis in 2019. From 2010 to 2019, the age-standardized incidence rate (ASIR) for cirrhosis increased slightly from 25.19 to 25.35 worldwide, while the age-standardized death rate (ASDR) and age-standardized DALYs (ASDALYs) decreased from 20.37 to 18.00 and 639.86 to 560.43, respectively. Cirrhosis incidence, mortality and DALYs were consistently higher in males than females. Stratification according to the socio-demographic index (SDI) revealed that low SDI countries had the highest ASDR and ASDALYs in 2019, while middle SDI countries had the highest ASIR. Regarding the aetiology of cirrhosis, hepatitis C accounted for the largest proportion of cirrhosis-related incidence (26.9%), death (26.8%) and DALYs (26.3%); however, non-alcoholic fatty liver disease (NAFLD) exhibited a rapidly growing cause of incident cirrhosis (+26.7%), cirrhosis-related death (+25.1%), and DALYs (+21.0%) worldwide during this period. The ASIR for NAFLD also significantly increased with APC 1.080 over the study period.
conclusionsAlbeit the global burden of cirrhosis incidence increased from 2010 to 2019, cirrhosis-associated deaths and DALYs declined significantly. Notably, NAFLD exhibited the most significant increase as a contributor to cirrhosis worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.